September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
One-year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO study
Author Affiliations & Notes
  • Yuji Oshima
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Kenichi Kimoto
    Ophthalmology, Oita University Faculty of Medicine, Yufu, Japan
  • Noriko Yoshida
    Ophthalmology, Shinshu University School of Medicine, Matsumoto, Japan
  • Kimihiko Fujisawa
    Ophthalmology, Japan Community Health care Organization Kyushu Hospital, Kitakyushu, Japan
  • Shozo Sonoda
    Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
  • Toshiaki Kubota
    Ophthalmology, Oita University Faculty of Medicine, Yufu, Japan
  • Toshinori Murata
    Ophthalmology, Shinshu University School of Medicine, Matsumoto, Japan
  • Taiji Sakamoto
    Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
  • Koh-Hei Sonoda
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Tatsuro Ishibashi
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Footnotes
    Commercial Relationships   Yuji Oshima, Bayer (F); Kenichi Kimoto, None; Noriko Yoshida, None; Kimihiko Fujisawa, None; Shozo Sonoda, None; Toshiaki Kubota, None; Toshinori Murata, None; Taiji Sakamoto, None; Koh-Hei Sonoda, None; Tatsuro Ishibashi, None
  • Footnotes
    Support  JSPS KAKENHI Grant # Kiban C26462641
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3693. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Yuji Oshima, Kenichi Kimoto, Noriko Yoshida, Kimihiko Fujisawa, Shozo Sonoda, Toshiaki Kubota, Toshinori Murata, Taiji Sakamoto, Koh-Hei Sonoda, Tatsuro Ishibashi; One-year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO study. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3693.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate one-year outcomes of intravitreal injection of aflibercept (IVA) in patients with polypoidal choroidal vasculopathy (PCV) in Japanese patients.

Methods : In this prospective, open-label, single-arm multicenter clinical trial, treatment naïve patients with PCV received intravitreal aflibercept (2.0 mg) every two months, after three initial monthly doses. The primary end point assessed was the proportion of patients maintaining baseline best-corrected visual acuity (BCVA) at one-year. BCVA change of 0.3 or more in log MAR VA was considered significant. Worsening in BCVA was defined as a decrease of > 0.3 log MAR units. Other key end points included change in BCVA and anatomic measures (Fisher’s extract test).

Results : Fifty eyes with PCV were included in this study. The proportions of patients with significant log MAR VA improvement or maintained was 97.6%. Mean Log MAR BCVA at baseline was 0.33 and improved to 0.12 Log MAR after one-year aflibercept treatment (p<0.001). The average central foveal thickness decreased from 356μm to 239μm (p<0.001). Complete regression rate of polypoidal lesions was seen in 54.8% after six months of treatment, and 72.5% after one-year of treatment. Ocular and systemic adverse events were encountered in six cases (herpetic keratitis 2%, subretinal hemorrhage 2%).

Conclusions : IVA is well tolerated in eyes with Japanese PCV patients. One-year outcomes of aflibercept treatment for Japanese patients with PCV resulted in stabilization of visual acuity accompanied by anatomical improvement. IVA monotherapy is effective for PCV patients with complete regression of polypoidal lesion.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×